Hemab Therapeutics Holdings Q3 2026 earnings

COAG · 2026-11-10 07:08 BMO ET · 8-K on SEC · 10-Q on SEC

Operating expenses increased 14% YoY to $29.8M, widening the net loss to $27.3M, despite a 4% increase in interest income.

Headline numbers

not stated in the 8-K

Revenue breakdown

not stated in the 8-K

Margins and costs

  • Gross margin not stated in the 8-K
  • Operating expenses $29.8M (+75% YoY)
  • One-offs in the quarter not stated in the 8-K
  • Effective tax rate 2.6% (prior-year 0.6%, year-to-date 1.1%)
  • Non-GAAP bridge No non-GAAP reconciliation provided.

KPIs

MetricActualPrior quarterPrior yearChange
Cash and cash equivalents$239.1M$237.4M$87.9M+0.7% QoQ, +171% YoY
Marketable securities$191.1M$220.1M$97.5M-13% QoQ, +96% YoY
Total assets$442.7M$467.8M$194.8M-5% QoQ, +127% YoY
Total stockholders' equity$429.3M$454.3M-$176.6M-5% QoQ, +344% YoY
Net cash used in operating activities-$72.5M-$44.2M-$44.8M+64% QoQ, +62% YoY
Net cash provided by financing activities$317.2M$317.1M-$0.1M0% QoQ, +3,172,600% YoY

Guidance

not stated in the 8-K

What drove it

  • Revenue story No revenue reported.
  • EPS story Net loss per share increased due to higher operating expenses and a 55% increase in weighted average shares outstanding.
  • One-off check not stated in the 8-K

The good

  • Interest income increased 1,473% YoY to $3.4M.
  • Cash and cash equivalents increased 171% YoY to $239.1M.
  • Total stockholders' equity turned positive to $429.3M.

The bad

  • Total operating expenses increased 75% YoY to $29.8M.
  • Net loss widened 60% YoY to $27.3M.
  • Weighted average shares outstanding increased 4,938% YoY to 46.7M.

The ugly

  • none

Open questions

  • What caused the 55% QoQ increase in weighted average shares outstanding?
  • What caused the 13% QoQ decrease in marketable securities?
  • What caused the 64% QoQ increase in cash used in operating activities?
Full release

Hemab Therapeutics Holdings (COAG) earnings release, November 10, 2026

Hemab Therapeutics Holdings, Inc. (COAG) · Form 8-K, Item 2.02 · Filed · SEC filing

Hemab Therapeutics Reports Third Quarter 2026 Financial Results and Provides

Corporate Update

Dosed first participant in Phase 1 clinical trial of

HMB-003 for management of heavy menstrual bleeding, a condition affecting more than 23 million women in the U.S. alone

Announced data showing

HMB-003 reduced severe menstrual bleeding in a cynomolgus monkey model; data to be presented at the 68th ASH Annual Meeting and Exposition in December 2026

Announced first clinical data for sutacimig in Factor VII deficiency (FVIID), showing shortening of prothrombin time by more than 50% in both participants and ~5x accumulation of endogenous FVII(a) in the participant with PK/PD data, after a single dose; updated Phase 2b data to be presented at ASH in

December 2026

Initiated

SOLARA, a pivotal Phase 3 trial of once-weekly subcutaneous sutacimig in Glanzmann thrombasthenia (GT), the first pivotal trial of a subcutaneous prophylactic treatment in GT

Expects to present data from the ongoing VELORA Pioneer Phase 1/2 trial of

HMB-002 in Von Willebrand

Disease at the 20th EAHAD (European Association for Haemophilia and

Allied Disorders) Congress in

February 2027

Strengthened Board of Directors with the appointment of Keli Walbert bringing two decades of commercial leadership and proven track record of successful launches to Hemab

CAMBRIDGE, MA, USA

& COPENHAGEN, Denmark – November 10, 2026 — Hemab Therapeutics (Nasdaq: COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience, today announced financial results for the third quarter ended September 30, 2026, and recent business highlights.

“We are excited to have started our Phase 3 study in Glanzmann thrombasthenia, transitioning Hemab to a biotech company with clinical stage programs ranging from Phase 1 to Phase 3 across our portfolio,” said Benny Sørensen, MD, PhD, CEO of Hemab. “As our programs advance, we continue to expand our development efforts for larger, underserved markets across coagulation disorders, from the high-severity populations we started with to conditions like heavy menstrual bleeding that affect millions of women each year. We are also excited to have dosed our first participant in the Phase 1 trial of

HMB-003 in heavy menstrual bleeding, and look forward to sharing additional preclinical and clinical data from all three programs in the coming months.”

Corporate Highlights

Recent Business Highlights and Anticipated Milestones

Sutacimig:

Sutacimig is a bispecific antibody in clinical development for two indications: GT and Factor VII deficiency (FVIID). Sutacimig has received

Fast Track, Orphan Drug, and Breakthrough Therapy Designations from the U.S. Food and Drug Administration (FDA) for the treatment of GT. In Europe, the European Medicines Agency (EMA) has granted sutacimig Orphan Medicinal Product designation for the treatment of GT and access to the Priority Medicines (PRIME) scheme. Sutacimig has also received the Innovative Licensing and Access Pathway (ILAP) designation from the UK Medicines and Healthcare products Regulatory Agency (MHRA).

Glanzmann Thrombasthenia:

GT is a congenital, severe, lifelong bleeding disorder caused by defects in platelet aggregation, with substantial geographic variation in prevalence, from approximately 1 in 100,000 individuals in high-prevalence regions such as the Gulf Cooperation Council (GCC) countries to between 1 in 350,000 and 1 in 600,000 in the United States. There are currently no approved prophylactic treatment options for GT; management is limited to platelet transfusions, antifibrinolytics, recombinant Factor VIIa, and bone marrow transplantation.

Factor VII Deficiency:

FVIID is a congenital severe bleeding disorder, with prevalence of moderate and severe forms estimated at approximately 1 in 500,000 globally and characterized by impaired blood clotting and increased bleeding risk.

HMB-002

- Von Willebrand Disease:

HMB-002 is a novel monovalent antibody designed for subcutaneous prophylactic treatment of VWD, the most common inherited bleeding disorder, with approximately 140,000 patients diagnosed across all severity levels in the United States, of whom more than an estimated 50,000 require treatment for bleeding events.

HMB-003

- Novel

Antifibrinolytic Program:

HMB-003 is a novel fatty-acid-conjugated peptide antifibrinolytic, designed to stabilize clots and reduce bleeding across multiple settings, beginning in heavy menstrual bleeding, an indication affecting one in three reproductive-age women, over 23 million women, in the U.S.

Third Quarter 2026 Financial Results

Conference Call Information

: The Company will host a conference call and webcast today at 8:00 a.m. ET.

Listeners can register for the webcast on the investors page of the company’s website (https://ir.hemab.com/) or directly through this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available on the company’s website approximately two hours after the call’s conclusion and will be available for approximately 90 days following the call. Those who plan on participating are advised to join 15 minutes prior to the start time.

About Glanzmann Thrombasthenia

Glanzmann thrombasthenia (GT) is a severe bleeding disorder marked by debilitating, sometimes life-threatening bleeding episodes. Results from an international natural history study (Glanzmann’s 360) revealed the substantial burden of this disease: 88% of the 117 participants reported at least one bleed in the previous week with 65% requiring a bleed-related hospital visit in the prior six months.... (truncated) mental health and quality of life, with over 80% having missed work or school, over 50% facing limitations in attending social events, and over 50% experiencing restrictions in travel.

To date, there are no approved prophylactic treatment options for GT.

About Factor VII Deficiency

Factor VII deficiency (FVIID) is a congenital severe bleeding disorder characterized by reduced levels of Factor VII, a naturally circulating blood coagulation protein. Patients with clinically severe FVIID suffer from recurrent, unpredictable, life-threatening or potentially disabling bleeding at critical sites, such as in the central nervous system, gastrointestinal tract and intra-articular locations, as well as recurrent mucocutaneous bleeds of the nose and gums with additional risks for female patients, consisting of heavy menstrual bleeding and potentially life-threatening post-partum hemorrhage.

About Sutacimig (formerly

HMB-001)

Sutacimig is a subcutaneously administered bispecific antibody that is designed to bind and stabilize endogenous Factor VIIa with one antibody arm and bind to

TLT-1 on activated platelets with the other arm. This mechanism is designed to allow for the accumulation of endogenous Factor VIIa in the body and recruitment of Factor VIIa directly to the surface of the activated platelets, where it amplifies thrombin generation at the platelet surface. Sutacimig is designed to be a first-in-class prophylactic treatment for Glanzmann thrombasthenia (GT) with the potential to treat other debilitating bleeding disorders. The U.S. Food and Drug Administration has granted Fast Track Designation, Orphan Drug Designation, and Breakthrough Therapy Designation to sutacimig for the treatment of GT, and the UK Medicines and Healthcare products Regulatory Agency has awarded sutacimig designation under the Innovative Licensing and Access Pathway (ILAP); it has been designated as an orphan medicinal product in the European Union for the treatment of GT, and the European Medicines Agency (EMA) has granted sutacimig access to the Priority Medicines (PRIME) scheme. For more information, please visit clinicaltrials.gov (NCT06211634).

About Von Willebrand Disease

Von Willebrand Disease

(VWD) is the most common inherited bleeding disorder, characterized by quantitative or qualitative defects in Von Willebrand Factor (VWF), often resulting in frequent mucocutaneous bleeding events and heavy menstrual bleeding in women. The severity of bleeding ranges from low-volume events to potentially life-threatening hemorrhages. Chronic blood loss frequently leads to iron deficiency anemia, exacerbating the disease burden and reducing quality of life, particularly for those with clinically understated subtypes. Despite its prevalence, current treatment options for VWD primarily focus on managing symptoms rather than addressing the underlying biology of the disease.

About Heavy Menstrual Bleeding

Heavy menstrual bleeding is a common condition characterized by excessive menstrual blood loss that disrupts a person’s physical, emotional, social, and daily life, affecting an estimated one in three reproductive-age women, or more than 23 million women in the U.S. alone. The condition is frequently associated with pain, iron-deficiency anemia, and fatigue, and carries a significant social burden, including stigma and substantial lost days from work and school.

Current treatment options are limited. Tranexamic acid (TXA), the primary non-hormonal therapy, has a short half-life that requires frequent dosing throughout menstruation, limiting adherence. Hormonal therapies are not suitable, or not preferred, for many women. To date, there remains no approved non-hormonal, customized hemostatic treatment option for heavy menstrual bleeding.

About

HMB-002

HMB-002 is a monovalent human antibody being developed as the first-in-class subcutaneous prophylactic treatment for Von Willebrand Disease targeting the underlying cause of the disease, a condition driven by a deficiency or defect in Von Willebrand Factor (VWF), a key regulator of hemostasis. By specifically targeting the

C-terminal

CK domain of VWF, which is distinct from regions critical to its essential interactions,

HMB-002 shields the protein from degradation, boosting endogenous levels without compromising its function. Clinical and nonclinical data suggest strong potential for meaningful therapeutic benefit. For more information, please visit clinicaltrials.gov

(NCT06610201 and NCT06754852).

About

HMB-003

HMB-003 is a subcutaneously administered peptide-based plasmin inhibitor with a durable half-life — a proven therapeutic target in coagulation medicine — being developed as a novel antifibrinolytic designed to reduce bleeding across multiple settings. Engineered to directly inhibit plasmin at its active site,

HMB-003 blocks fibrinolysis independently of the plasminogen activation pathway.

HMB-003 is optimized to provide sustained bleed protection across multiple high-unmet-need conditions, ranging from heavy menstrual bleeding and hereditary hemorrhagic telangiectasia to peri-operative bleeding management. For more information, please visit clinicaltrials.gov (NCT07798505).

About Hemab Therapeutics

Hemab Therapeutics Holdings,

Inc. is a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience. Hemab’s mission is to discover, develop, and commercialize innovative therapies for the millions of patients worldwide suffering from serious bleeding and thrombotic diseases. Hemab is building a franchise of innovative therapeutics designed to address critical gaps in the treatment of coagulation disorders, including sutacimig

(HMB-001), a bispecific antibody in clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency,

HMB-002, a... (truncantibody in clinical development for the prophylactic treatment of Von Willebrand Disease, and

HMB-003, an antifibrinolytic targeting plasmin inhibition in clinical development for heavy menstrual bleeding.

Learn more at hemab.com. Follow us on

LinkedIn,

Facebook,

Instagram, and

X.

Financial statements

Income Statement

Three Months Ended September 30, — (Unaudited) (in thousands)

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Operating expenses
Research and development24,63914,55564,43641,530
General and administrative5,1192,50015,0138,142
Total operating expenses29,75817,05579,44949,672
Loss from operations-29,758-17,055-79,449-49,672
Other income (expense), net
Interest income3,3842157,4611,023
Other income (expense), net-237-127-1,3513,981
Other income (expense), net
Total other income, net3,147886,1105,004
Loss before income tax expense-26,611-16,967-73,339-44,668
Income tax (expense) benefit-693-98-80288
Net loss-27,304-17,065-74,141-44,580
Net loss per share, basic and diluted-0.58-18.04-2.84-47.12
Weighted average shares outstanding, basic and diluted46,712,044946,00026,090,769946,000
Other comprehensive income (loss)
Net loss-27,304-17,065-74,141-44,580
Net unrealized (loss) gain on available-for-sale debt securities96-2,827365
Reclassification of realized loss on available-for- sale debt securities11
Total other comprehensive income (loss)97-2,826365
Total comprehensive loss-27,207-17,065-76,967-44,215

Balance Sheet

September 30, 2026 — (Unaudited) (in thousands)

September 30, 2026December 31, 2025
Assets
Cash and cash equivalents239,14987,974
Marketable securities191,08997,511
Prepaid expenses and other current assets7,9207,066
Property and equipment, net555609
Operating right-of-use assets8501,092
Other non-current assets3,149531
Total assets442,712194,783
Liabilities and stockholders’ equity (deficit)
Accounts payable5,9525,734
Operating lease liabilities462647
Operating lease liabilities, net of current portion503573
Accrued expenses and other current liabilities6,5264,296
Total liabilities13,44311,250
Total convertible preferred stock and convertible preference shares360,168
Total stockholders’ equity (deficit)429,269-176,635

Cash Flow

Nine Months Ended September 30, — (Unaudited) (in thousands)

Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025Nine Months Ended September 30, – Change
Net cash used in operating activities-72,512-44,761-27,751
Net cash (used in) provided by investing activities-93,18015,508-108,688
Net cash provided by (used in) financing activities317,166-89317,255
Effect of foreign exchange rate changes on cash and cash equivalents-299-299
Net increase (decrease) in cash and cash equivalents151,175-29,342180,517

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release, including statements regarding Hemab’s strategy, future operations, prospects and plans, objectives of management, the anticipated timing of reporting and presenting preclinical and clinical data, including from the Phase 1 trial of

HMB-003, the anticipated enrollment, timing of entry into the run-in period, conduct and progression of the SOLARA Phase 3 clinical trial of sutacimig, the suitability of SOLARA’s single-arm, intra-participant trial design for evaluating sutacimig in GT, the potential for the design and results of SOLARA to support regulatory approval of sutacimig, the clinical potential of sutacimig,

HMB-002 and

HMB-003, including their potential therapeutic benefits and use across additional indications,

Hemab’s plans to expand its pipeline, and the sufficiency of Hemab’s cash resources for the period anticipated, constitute forward-looking statements within the meaning of The Private Securities

Litigation Reform Act of 1995. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,”

“intend,” “may,” “might,” “objective,” “ongoing,” “plan,” “predict,” “project,” “potential,” “should,” or “would,” or the negative of these terms, or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Hemab may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including: uncertainties inherent in the identification and development of product candidates, including the initiation and completion of preclinical studies and clinical trials; uncertainties as to the availability and timing of results from preclinical studies and clinical trials; the timing of and Hemab’s ability to initiate and enroll patients in clinical trials; whether results from preclinical studies and earlier clinical trials will be predictive of the results of later clinical trials; the risk that the FDA or other regulatory authorities may not agree that SOLARA’s single-arm, intra-participant design is adequate to establish the safety or effectiveness of sutacimig for GT, may not accept the results of SOLARA as substantial evidence supporting approval, or may require Hemab to conduct one or more additional clinical trials, including a randomized controlled trial, before submitting or obtaining approval of a marketing application for sutacimig; the risk that Hemab’s decision to proceed with the current SOLARA design notwithstanding the FDA’s recommendation that Hemab consider a randomized controlled design could result in delays in, additional costs associated with, or the inability to obtain regulatory approval for sutacimig on the timeline anticipated or at all; whether Hemab’s cash resources will be sufficient to fund Hemab’s foreseeable and unforeseeable operating expenses and capital expenditure requirements; as well as the risks and uncertainties identified in Hemab’s filings with the Securities and Exchange Commission (SEC), including

Hemab’s most recent Form

10-Q and in subsequent filings Hemab may make with the SEC. In addition, the forward-looking statements included in this press release represent Hemab’s views as of the date of this press release. Hemab anticipates that subsequent events and developments will cause its views to change. However, while Hemab may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Hemab’s views as of any date subsequent to the date of this press release.

Media:

Deerfield Group

Peg Rusconi peg.rusconi@deerfieldgroup.com

Investors:

Hemab Therapeutics

Mads Behrndt investors@hemab.com

Hemab Therapeutics Holdings, Inc.

Condensed Consolidated Statements of Operations and Comprehensive Loss

(In thousands, except share and per share data)

(Unaudited)

Hemab Therapeutics Holdings, Inc.

Selected Condensed Consolidated Balance Sheet Data

(In thousands)

(Unaudited)

Hemab Therapeutics Holdings, Inc.

Selected Condensed Consolidated Statements of Cash Flows Data

(In thousands)

(Unaudited)

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Hemab Therapeutics Holdings earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.